{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"138"}],"units":"Participants"}],"description":"According to RECIST v 1.1, CNS progression was defined as \\>/=20% increase in the SoD of measurable CNS lesions (with an absolute increase of at least 5 mm), taking as reference the baseline SoD; 1 or more new CNS lesion(s); and/or unequivocal progression of non-measurable CNS lesions.","groups":[{"description":"Participants received alectinib at a dose of 600 mg via capsule, orally, twice daily, continuously starting on Day 1 Cycle 1 (in 28-day cycles) until PD, death, or withdrawal for any other reasons, whichever occurred first. After PD, participants were allowed to continue treatment with alectinib as per the discretion of the treating physician.","id":"OG000","title":"Alectinib"}],"paramType":"NUMBER","populationDescription":"Analysis was performed on safety population.","reportingStatus":"POSTED","timeFrame":"Baseline; assessments every 8 weeks post-baseline until progressive disease, unacceptable toxicity, consent withdrawal, death, other reason deemed by investigator; then survival follow-up until cutoff 18 August 2014 (up to approximately 53 weeks)","title":"Percentage of Participants With CNS Progression as Assessed by IRC According to RECIST v 1.1","type":"SECONDARY","unitOfMeasure":"percentage of participants"}